GlassScriptPhysician profile
Ilysa Bartol
NPI 1447820097
$2,392.21
in general payments reported to CMS, 2019-2025
21 companies · $698 in 2025
The $698 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.37 · 2023: $713 · 2024: $958 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.99 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $801.34 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $244.56 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $203.30 | 2023-2025 | |
| Pfizer INC. | $173.34 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $169.06 | 2024-2025 | Gemtesa |
| Lundbeck LLC | $154.80 | 2022-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $88.30 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.02 | 2023-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $70.42 | 2023-2024 | Rexulti |
| Organon LLC | $65.67 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $62.24 | 2025 | Airsupra, Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $58.95 | 2025 | Voquezna |
| Amgen INC. | $51.29 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Shield Therapeutics INC | $30.68 | 2023 | Accrufer |
| Inspire Medical Systems, INC. | $30.50 | 2025 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.85 | 2025 | Trintellix |
| Xeris Pharmaceuticals, INC. | $18.94 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $16.27 | 2023 | Auvelity |
| Exact Sciences Corporation | $16.02 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $13.49 | 2023 | Quviviq |
| Phadia US INC. | $13.17 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilysa Bartol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.